Porton Fine Chemicals Ltd (300363) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.023x

Based on the latest financial reports, Porton Fine Chemicals Ltd (300363) has a cash flow conversion efficiency ratio of 0.023x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥126.55 Million ≈ $18.52 Million USD) by net assets (CN¥5.49 Billion ≈ $803.76 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 300363 market cap overview for the company's overall valuation and market capitalisation.

Porton Fine Chemicals Ltd - Cash Flow Conversion Efficiency Trend (2009–2024)

This chart illustrates how Porton Fine Chemicals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Porton Fine Chemicals Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Porton Fine Chemicals Ltd ranked by their cash flow conversion efficiency. Explore Porton Fine Chemicals Ltd cash earnings quality to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Fibra Terrafina
MX:TERRA13
0.027x
Shenzhen Qingyi Photomask Ltd
SHG:688138
0.031x
CoCreation Grass Co Ltd
SHG:605099
0.002x
Guangzhou Goaland Energy Conservation Tech Co Ltd
SHE:300499
0.027x
Soulbrain Co. Ltd
KQ:357780
0.047x
Yusys Technologies Co Ltd Class A
SHE:300674
0.008x
Harbin Boshi Automation Co Ltd
SHE:002698
0.010x
Albany International Corporation
NYSE:AIN
0.008x

Annual Cash Flow Conversion Efficiency for Porton Fine Chemicals Ltd (2009–2024)

The table below shows the annual cash flow conversion efficiency of Porton Fine Chemicals Ltd from 2009 to 2024. View Porton Fine Chemicals Ltd (300363) stock price for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CN¥5.41 Billion
≈ $791.83 Million
CN¥405.53 Million
≈ $59.34 Million
0.075x -27.33%
2023-12-31 CN¥6.10 Billion
≈ $892.61 Million
CN¥629.06 Million
≈ $92.05 Million
0.103x -73.97%
2022-12-31 CN¥6.47 Billion
≈ $947.10 Million
CN¥2.56 Billion
≈ $375.26 Million
0.396x +245.42%
2021-12-31 CN¥4.19 Billion
≈ $612.56 Million
CN¥480.17 Million
≈ $70.26 Million
0.115x -22.83%
2020-12-31 CN¥3.39 Billion
≈ $496.54 Million
CN¥504.37 Million
≈ $73.81 Million
0.149x +29.63%
2019-12-31 CN¥3.06 Billion
≈ $448.41 Million
CN¥351.37 Million
≈ $51.42 Million
0.115x +70.75%
2018-12-31 CN¥2.88 Billion
≈ $421.91 Million
CN¥193.62 Million
≈ $28.33 Million
0.067x -66.38%
2017-12-31 CN¥1.45 Billion
≈ $212.07 Million
CN¥289.46 Million
≈ $42.36 Million
0.200x -4.09%
2016-12-31 CN¥1.37 Billion
≈ $200.49 Million
CN¥285.33 Million
≈ $41.75 Million
0.208x +118.72%
2015-12-31 CN¥1.18 Billion
≈ $172.60 Million
CN¥112.31 Million
≈ $16.43 Million
0.095x -31.71%
2014-12-31 CN¥874.42 Million
≈ $127.96 Million
CN¥121.92 Million
≈ $17.84 Million
0.139x -47.62%
2013-12-31 CN¥428.43 Million
≈ $62.69 Million
CN¥114.05 Million
≈ $16.69 Million
0.266x -23.60%
2012-12-31 CN¥327.76 Million
≈ $47.96 Million
CN¥114.21 Million
≈ $16.71 Million
0.348x +31.02%
2011-12-31 CN¥246.01 Million
≈ $36.00 Million
CN¥65.43 Million
≈ $9.57 Million
0.266x +21.40%
2010-12-31 CN¥163.21 Million
≈ $23.88 Million
CN¥35.75 Million
≈ $5.23 Million
0.219x -44.12%
2009-12-31 CN¥81.60 Million
≈ $11.94 Million
CN¥31.99 Million
≈ $4.68 Million
0.392x --

About Porton Fine Chemicals Ltd

SHE:300363 China Drug Manufacturers - Specialty & Generic
Market Cap
$1.69 Billion
CN¥11.53 Billion CNY
Market Cap Rank
#6782 Global
#1387 in China
Share Price
CN¥21.22
Change (1 day)
-1.16%
52-Week Range
CN¥13.32 - CN¥29.41
All Time High
CN¥97.10
About

Porton Pharma Solutions Ltd. provides contract development and manufacturing organization (CDMO) solutions for small molecules, tides, biologics, and conjugates from pre-clinical to commercial. It has a strategic collaboration with Aojin Life Sciences to advance XDC conjugate drugs; and strategic partnership with Dragon Sail Pharmaceutical to build a new ecosystem for ADC drug development, produc… Read more